Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:LIFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LIFE Guru Trades in Q1 2016

RS Investment Management 1,579,892 sh (+30.98%)
» More
Q2 2016

LIFE Guru Trades in Q2 2016

RS Investment Management Sold Out
» More
Q3 2016

LIFE Guru Trades in Q3 2016

Jim Simons 69,200 sh (New)
» More
Q4 2016

LIFE Guru Trades in Q4 2016

Jim Simons 38,100 sh (-44.94%)
» More
» Details

Insider Trades

Latest Guru Trades with LIFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ORMP, AMEX:ATNM, NAS:ARQL, NAS:NEPT, AMEX:XXII, NAS:AKTX, NAS:FLKS, NAS:ONS, NAS:CASI, OTCPK:NEWG, NAS:AXSM, NAS:AFMD, NAS:SNSS, NAS:TTNP, NAS:CFRX, NAS:NOVN, NAS:PIRS, NAS:SBPH, OTCPK:CNNRF, OTCPK:SLNCF » details
Traded in other countries:471.Germany,
aTyr Pharma Inc is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.

aTyr Pharma Inc was incorporated in the state of Delaware on September 8, 2005. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The Company is currently conducting a multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD in the European Union. This randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple intravenous doses of Resolaris in adults with FSHD. Its initial therapeutic efforts target severe, rare disease indications in which patients suffer from the immune-related consequences of their genetic disease. It contracts with third parties for the manufacturing and testing of its product candidates for preclinical studies and clinical trials. It does not own or operate manufacturing facilities for the production of clinical quantities of its product candidates. Government authorities in the United States, including federal, state, and local authorities, and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical and biological products, such as those it is developing.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

EPS (TTM) $ -2.56
Short Percentage of Float5.67%
52-Week Range $2.10 - 6.41
Shares Outstanding (Mil)23.72
» More Articles for NAS:LIFE

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
High court ruling limits international reach of patent laws Feb 22 2017
High court ruling limits international reach of patent laws Feb 22 2017
Atyr Pharma Stock Spikes 33% on FDA Updates Jan 19 2017
FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B... Jan 18 2017
ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure Jan 09 2017
Roberts recuses from patent case after discovering conflict Jan 04 2017
Roberts recuses from patent case after discovering conflict Jan 04 2017
Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares Dec 21 2016
Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers? Dec 16 2016
aTyr Pharma downgraded by JP Morgan Dec 13 2016
aTyr Pharma Drops on Clinical Update Dec 13 2016
ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events Dec 13 2016
aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct... Dec 13 2016
aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference Dec 09 2016
aTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 Dec 05 2016
ATYR PHARMA INC Financials Nov 23 2016
aTyr Pharma Enters into $20 Million Credit Facility Nov 21 2016
ATYR PHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Nov 21 2016
aTyr Pharma Enters into $20 Million Credit Facility Nov 21 2016
aTyr Pharma (LIFE) Looks Good: Stock Adds 5.9% in Session Nov 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)